BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,269,002 | -19.8% | 239,004 | -3.8% | 0.02% | -13.8% |
| Q2 2023 | $20,286,851 | +8.4% | 248,522 | -1.5% | 0.03% | +3.6% |
| Q1 2023 | $18,723,182 | -11.4% | 252,368 | -1.0% | 0.03% | -15.2% |
| Q4 2022 | $21,126,278 | +16.8% | 254,902 | +300.1% | 0.03% | +6.5% |
| Q3 2022 | $18,093,000 | -19.2% | 63,706 | -1.4% | 0.03% | -11.4% |
| Q2 2022 | $22,396,000 | -21.0% | 64,609 | -1.3% | 0.04% | -5.4% |
| Q1 2022 | $28,343,000 | -20.9% | 65,451 | -5.4% | 0.04% | -11.9% |
| Q4 2021 | $35,812,000 | +9.2% | 69,223 | +2.3% | 0.04% | 0.0% |
| Q3 2021 | $32,784,000 | +4.9% | 67,655 | -2.5% | 0.04% | +7.7% |
| Q2 2021 | $31,257,000 | +19.0% | 69,421 | +1.0% | 0.04% | +11.4% |
| Q1 2021 | $26,264,000 | +21.0% | 68,766 | +0.6% | 0.04% | +16.7% |
| Q4 2020 | $21,700,000 | +30.8% | 68,336 | +2.1% | 0.03% | +11.1% |
| Q3 2020 | $16,588,000 | -3.8% | 66,960 | +2.5% | 0.03% | -10.0% |
| Q2 2020 | $17,244,000 | +41.1% | 65,300 | +1.3% | 0.03% | +15.4% |
| Q1 2020 | $12,220,000 | -14.8% | 64,443 | -1.3% | 0.03% | +8.3% |
| Q4 2019 | $14,337,000 | +21.4% | 65,314 | +8.2% | 0.02% | +4.3% |
| Q3 2019 | $11,813,000 | -5.0% | 60,371 | +1.2% | 0.02% | -8.0% |
| Q2 2019 | $12,437,000 | +6.5% | 59,651 | +1.4% | 0.02% | +4.2% |
| Q1 2019 | $11,681,000 | +37.8% | 58,833 | +0.4% | 0.02% | +26.3% |
| Q4 2018 | $8,477,000 | -27.4% | 58,575 | +2.4% | 0.02% | -17.4% |
| Q3 2018 | $11,678,000 | +37.9% | 57,214 | -0.0% | 0.02% | +27.8% |
| Q2 2018 | $8,468,000 | -1.0% | 57,235 | +1.1% | 0.02% | 0.0% |
| Q1 2018 | $8,552,000 | +12.6% | 56,624 | -3.4% | 0.02% | +12.5% |
| Q4 2017 | $7,593,000 | +5.6% | 58,610 | -1.5% | 0.02% | 0.0% |
| Q3 2017 | $7,193,000 | -7.0% | 59,502 | -9.6% | 0.02% | 0.0% |
| Q2 2017 | $7,734,000 | +4.3% | 65,821 | -9.8% | 0.02% | +6.7% |
| Q1 2017 | $7,417,000 | -5.6% | 72,964 | -4.5% | 0.02% | -6.2% |
| Q4 2016 | $7,853,000 | -8.5% | 76,364 | -2.6% | 0.02% | -11.1% |
| Q3 2016 | $8,581,000 | -2.1% | 78,364 | +0.8% | 0.02% | -5.3% |
| Q2 2016 | $8,769,000 | +15.4% | 77,764 | -3.2% | 0.02% | +18.8% |
| Q1 2016 | $7,596,000 | +20.2% | 80,359 | +14.5% | 0.02% | +6.7% |
| Q4 2015 | $6,317,000 | -1.0% | 70,185 | +1.7% | 0.02% | -11.8% |
| Q3 2015 | $6,384,000 | -4.5% | 69,041 | +1.7% | 0.02% | +6.2% |
| Q2 2015 | $6,683,000 | -3.3% | 67,870 | -1.5% | 0.02% | 0.0% |
| Q1 2015 | $6,914,000 | +7.0% | 68,937 | -1.4% | 0.02% | +6.7% |
| Q4 2014 | $6,461,000 | – | 69,926 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |